12-GI-86 NP BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors

Grants and Contracts Details

StatusFinished
Effective start/end date7/1/139/30/15

Funding

  • Novartis (domestic): $20,896.00